Marinus selling rare pediatric disease priority review voucher for $110M
July 14, 2022 at 11:07 AM EDT
The FDA awarded the Radnor company the lucrative voucher after its seizure drug Ztalmy was approved in March.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|